We are live on
!
Find out more
MC
Mayo Clinic Portfolio holdings
AUM
$2.9M
1-Year Est. Return
14.49%
This Fund
S&P 500
This Quarter
Est. Return
+32.06%
1 Year Est. Return
+14.49%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$83.1M
AUM Growth
+$8.91M
(+12%)
Cap. Flow
+$1.24M
Cap. Flow
% of AUM
1.49%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRNE
Sorrento Therapeutics, Inc.
SRNE
|
+$5.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
+$3.62M |
| 2 |
EXAS
Exact Sciences
EXAS
|
+$240K |
| 3 |
VYNT
Vyant Bio, Inc. Common Stock
VYNT
|
+$184K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.13% |
| 2 | Energy | 45.97% |
| 3 | Miscellaneous | 7.43% |
| 4 | Financials | 0.47% |
Similar funds
SWS
PWA
CU
QC
SOA
HVM
JC
MIG
Mayo Clinic's Q4 2020 Portfolio in Review
As of Q4 2020, Mayo Clinic held 10 positions worth $83.1M, up 12% from $74.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Mayo Clinic's Q4 2020 filing shows 1 new, 2 reduced and 1 closed positions. Its largest new stake was Sorrento Therapeutics, Inc.: 657,877 shares worth $4.49M. The largest sale was Zentalis Pharmaceuticals, an estimated $3.62M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 39% a quarter earlier, followed by Energy and Miscellaneous.
- Mayo Clinic's largest Q4 2020 buy was Sorrento Therapeutics, Inc.: 657,877 shares worth $4.49M.
- Mayo Clinic's biggest Q4 2020 reduction was Zentalis Pharmaceuticals, cutting an estimated $3.62M.
- Mayo Clinic fully exited Vyant Bio, Inc. Common Stock in Q4 2020, selling an estimated $184K.
- Mayo Clinic's ten largest holdings make up 100% of its $83.1M portfolio in Q4 2020.
- Mayo Clinic opened 1 new position and closed 1 in Q4 2020.
- Mayo Clinic's portfolio value rose 12% quarter-over-quarter to $83.1M.
Based on Mayo Clinic's 13F filing for Q4 2020, filed 11 Feb 2021.